跳至主要内容
临床试验/NCT01258452
NCT01258452已完成1 期

Randomized, Balanced, Single Dose, Cross-Over Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects

CERESPIR1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
CERESPIR
入组人数
12
试验地点
1
主要终点
peak CHF 5074 plasma concentration (Cmax)

研究概览

简要总结

To evaluate the effects of a high-calorie high-fat meal on the extent and rate of absorption of CHF 5074 after single oral administration in young healthy male volunteers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Subject is judged to be in good health on the basis of medical history, complete physical examination including vital signs, 12-lead electrocardiogram (ECG) and standard laboratory tests.
  • Subject has a body mass index between 18 and 30 kg/m^2, inclusive.

排除标准

  • Medical history (within the last 10 years) of major cardiovascular, hepatic or renal disease.
  • Abnormal result of liver function tests, renal function tests or thyroid tests performed at screening.
  • Significant allergic conditions that require medical treatment
  • Use of any psychoactive, recreational or prescription drug within the 4 weeks prior to study drug administration.
  • Use of ibuprofen, sulindac sulfide, indomethacin, flurbiprofen within 2 weeks prior to study drug administration.

研究组 & 干预措施

CHF 5074 (fed group)

Experimental

oral tablet, single dose

干预措施: CHF 5974 (Drug)

CHF 5074 (fasting group)

Experimental

oral tablet, single dose

干预措施: CHF 5074 (Drug)

结局指标

主要结局

peak CHF 5074 plasma concentration (Cmax)

时间窗: from Day 1 to Day 5

area under the curve of plasma CHF 5074 levels from 0 to 96 hours (AUC 0-96)

时间窗: from Day 1 to Day 5

次要结局

  • the time of occurrence of Cmax (Tmax)(from Day 1 to Day 5)

研究者

发起方
CERESPIR
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验